Search Results - bryan+haugen

5 Results

Sort By:

Human thyroid cancer cell line with the HRAS Q61R mutation

CU researchers have developed a human thyroid cancer cell line with the HRAS Q61R mutation. The cell line, called CUTC61, was derived from a 72-year-old female patient with metastatic follicular thyroid cancer (FTC) and was developed to study tumor progression and response to therapy. The CUTC61 cells can be used as in vitro cultured cell and patient-derived...

Published: 5/22/2023 | Inventor(s): Rebecca Schweppe, Bryan Haugen

Disease Areas Oncology

Category(s): Research Tools

Human thyroid cancer cell line with the BRAF V600E mutation

CU researchers have developed a human thyroid cancer cell line with the BRAF V600E mutation. The cell line, called CUTC60, was derived from a 59-year-old female patient with anaplastic thyroid cancer (PTC) and was developed to study tumor progression and response to therapy. The research team verified that the CUTC60 cells form tumors in orthotopic...

Published: 5/22/2023 | Inventor(s): Rebecca Schweppe, Bryan Haugen

Disease Areas Oncology

Category(s): Research Tools

Human thyroid cancer cell line with the BRAF V600E mutation

CU researchers have developed a human thyroid cancer cell line with the BRAF V600E mutation. The cell line, called CUTC5, was derived from a 73-year-old female patient with a malignant pleural effusion and was developed to study the underlying biology of thyroid cancer and response to therapy. The research team verified that the CUTC5 cells form tumors...

Published: 5/22/2023 | Inventor(s): Rebecca Schweppe, Bryan Haugen

Disease Areas Oncology

Category(s): Research Tools

Human thyroid cancer cell line that expresses the RET/PTC1 rearrangement

CU researchers have developed a human thyroid cancer cell line that expresses the RET/PTC1 rearrangement. The cell line, called CUTC48, was derived from a 68-year-old female patient with metastatic papillary thyroid cancer (PTC). CUTC48 cells do not form flank tumors in mouse models but do express high levels of the RET/PTC1 transcript and protein....

Published: 5/22/2023 | Inventor(s): Rebecca Schweppe, Bryan Haugen

Disease Areas Oncology

Category(s): Research Tools

A375 Melanoma Cell Line Resistant to LGD 1069, Thiazolidinediones, and the Combination

CU scientists have generated a human melanoma cell line that shows decreased proliferation in the presence of the RXR agonist LGD 1069, PPAR agonist rosiglitazone, and the combination. The cell line, called A375(DRO) cells, was created by slowly growing A375 melanoma cancer cells in the presence of each ligand or the combination. Importantly, the cell...

Published: 5/22/2023 | Inventor(s): Joshua Klopper, Bryan Haugen

Disease Areas Oncology

Category(s): Research Tools